Novogen lines up a double dose of funding
14 August, 2014 by Dylan Bushell-EmblingNovogen (ASX:NRT) has won shareholder approval to raise funds to bring drug candidates into clinical trials and support from a FSHD foundation for its regenerative program with Genea Biocells.
New malaria vaccine approach attracts collaboration
06 August, 2014 by Susan WilliamsonA collaboration between the Burnet Institute and ARTES Biotechnology will progress the development of and test a new strategy for a malaria vaccine.
UTS boffins develop blood test for oral cancers
29 July, 2014 by Dylan Bushell-EmblingResearchers from UTS have developed a fast and easy way to administer a blood test for detecting early warning signs of oral cancers.
IDT names US distributor for generic cancer drug
29 July, 2014 by Dylan Bushell-EmblingIDT Australia has signed an exclusive distribution deal with Mayne Pharma for melanoma and glioblastoma multiforme treatment generic temozolomide.
Bowel cancer test rolls out in Blue Mountains
28 July, 2014 by Dylan Bushell-EmblingClinical Genomics has launched a trial rollout of its jointly developed blood test for bowel cancer in the Blue Mountains.
Novogen picks CMOs for ovarian cancer drug
28 July, 2014 by Dylan Bushell-EmblingNovogen (ASX:NRT) joint venture CanTx has chosen two US-based CMOs to manufacture batches of Cantrixil, the ovarian cancer drug candidate it aims to take to the clinic in mid-2015.
Patrys commences CAR T cell research program
24 July, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) has started collaborative research into genetically engineering T cells against novel anticancer targets using its IgM antibodies.
Fellowships for research in Japan
24 July, 2014Postdoctoral, short- and long-term research fellowships are available to Australian researchers to work in Japan for 2015-2016.
ImpediMed picks Australian site for L-Dex trial
23 July, 2014 by Dylan Bushell-EmblingImpediMed (ASX:IPD) has named the Macquarie University Cancer Institute as the Australian site for a post-approval trial of L-Dex, its lymphodoema detection device.
Biotron's BIT225 reverses immune impairment in HIV
23 July, 2014 by Dylan Bushell-EmblingNew data from a trial of Biotron's (ASX:BIT) BIT225 in HIV show that patients treated daily demonstrated a reduction in sCD163 levels in the blood.
Developing guidelines for 'omics'-based tests
23 July, 2014A new guide for 'omics'-based tests, focusing on genomic testing, has been released for public consultation by the NHMRC.
Virax appoints oncology guru to scientific board
21 July, 2014 by Dylan Bushell-EmblingVirax Holdings (ASX:VHL) has selected US cancer specialist Dr Joseph Sparano to lead phase I/IIb trials of breast cancer treatment candidate GGTI-2418.
Shutting the gate on the malaria parasite
18 July, 2014Blocking the malaria parasite's access to proteins needed for its survival may lead to the development of new treatments for this deadly disease.
New initiative for health research and its translation
17 July, 2014The NHMRC has launched the Advanced Health Research and Translation Centre initiative.
Prima picks up US patent for cancer treatment CVac
16 July, 2014 by Dylan Bushell-EmblingThe US patent office has approved Prima BioMed's (ASX:PRR) application for a patent protecting autologous cancer treatment candidate CVac.
